AU2015342908B2 - Dosage regimen for pegylated interferon - Google Patents

Dosage regimen for pegylated interferon Download PDF

Info

Publication number
AU2015342908B2
AU2015342908B2 AU2015342908A AU2015342908A AU2015342908B2 AU 2015342908 B2 AU2015342908 B2 AU 2015342908B2 AU 2015342908 A AU2015342908 A AU 2015342908A AU 2015342908 A AU2015342908 A AU 2015342908A AU 2015342908 B2 AU2015342908 B2 AU 2015342908B2
Authority
AU
Australia
Prior art keywords
interferon
treatment period
weeks
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015342908A
Other languages
English (en)
Other versions
AU2015342908A1 (en
Inventor
Christoph Klade
Ko-Chung Lin
Oleh ZAGRIJTSCHUK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharmaEssentia Corp
Original Assignee
PharmaEssentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharmaEssentia Corp filed Critical PharmaEssentia Corp
Publication of AU2015342908A1 publication Critical patent/AU2015342908A1/en
Application granted granted Critical
Publication of AU2015342908B2 publication Critical patent/AU2015342908B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2015342908A 2014-11-06 2015-11-06 Dosage regimen for pegylated interferon Active AU2015342908B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192114.8 2014-11-06
EP14192114 2014-11-06
PCT/US2015/059410 WO2016073825A1 (en) 2014-11-06 2015-11-06 Dosage regimen for pegylated interferon

Publications (2)

Publication Number Publication Date
AU2015342908A1 AU2015342908A1 (en) 2017-05-04
AU2015342908B2 true AU2015342908B2 (en) 2021-06-24

Family

ID=51945707

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015342908A Active AU2015342908B2 (en) 2014-11-06 2015-11-06 Dosage regimen for pegylated interferon

Country Status (32)

Country Link
US (3) US11559567B2 (enExample)
EP (2) EP4282485A3 (enExample)
JP (2) JP6820841B2 (enExample)
KR (2) KR102540109B1 (enExample)
CN (1) CN107530403A (enExample)
AU (1) AU2015342908B2 (enExample)
BR (1) BR112017009193A2 (enExample)
CA (1) CA2964390A1 (enExample)
CL (1) CL2017001088A1 (enExample)
DK (1) DK3215193T3 (enExample)
EA (1) EA037151B1 (enExample)
ES (1) ES2966888T3 (enExample)
FI (1) FI3215193T3 (enExample)
HK (1) HK1243627A1 (enExample)
HR (1) HRP20231732T1 (enExample)
HU (1) HUE064909T2 (enExample)
IL (1) IL251627B (enExample)
LT (1) LT3215193T (enExample)
MX (1) MX389844B (enExample)
MY (1) MY191506A (enExample)
NZ (1) NZ730924A (enExample)
PH (1) PH12017500617B1 (enExample)
PL (1) PL3215193T3 (enExample)
PT (1) PT3215193T (enExample)
RS (1) RS65015B1 (enExample)
SG (1) SG11201702798PA (enExample)
SI (1) SI3215193T1 (enExample)
SM (1) SMT202400028T1 (enExample)
TW (1) TWI737583B (enExample)
UA (1) UA122867C2 (enExample)
WO (1) WO2016073825A1 (enExample)
ZA (1) ZA201702704B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190374611A1 (en) * 2017-01-18 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
AU2022221496A1 (en) * 2021-08-29 2023-03-16 Pharmaessentia Corporation Method of Using Pegylated Interferon-alpha

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
RU2002105485A (ru) * 1999-08-13 2004-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
WO2001015736A2 (en) 1999-08-27 2001-03-08 Maxygen Aps Interferon-beta conjugates
JP2003513681A (ja) 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
KR20070072924A (ko) 2001-11-20 2007-07-06 파마시아 코포레이션 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
DK3025726T3 (da) 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
AP2005003246A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
PL380269A1 (pl) 2002-12-26 2007-01-08 Mountain View Pharmaceuticals, Inc. Koniugaty polimerowe cytokin, czynników wzrostu, hormonów polipeptydowych i ich antagonistów o zachowanej zdolności do wiązania receptora
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
CN101010105A (zh) 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法
US7365127B2 (en) 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1869079A2 (en) 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
EP1834963A1 (en) 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
US20090035273A1 (en) * 2006-08-18 2009-02-05 Pepgen Corporation Combination treatment method with interferon-tau
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2698396C (en) 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
CN101636414B (zh) 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
EA020347B1 (ru) 2008-07-31 2014-10-30 Фармаиссэншиа Корп. Пептид-полимерные конъюгаты
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
EP2646107A2 (en) * 2010-12-01 2013-10-09 Spinal Modulation Inc. Agent delivery systems for selective neuromodulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Anonymous, "Study Drugs - Proud-PV Phase III Study", (2014-06-03), URL: http://web.archive.org/web/2014-06-03131156/http://www.proud-pv.com/study-drugs.html, (2015-04-15) *

Also Published As

Publication number Publication date
CL2017001088A1 (es) 2018-01-12
JP6820841B2 (ja) 2021-01-27
ZA201702704B (en) 2020-10-28
DK3215193T3 (da) 2024-01-08
MX2017005244A (es) 2017-08-18
EP3215193A1 (en) 2017-09-13
PH12017500617A1 (en) 2017-09-04
HRP20231732T1 (hr) 2024-03-15
KR102724837B1 (ko) 2024-10-31
US20170326206A1 (en) 2017-11-16
MY191506A (en) 2022-06-28
JP2021001184A (ja) 2021-01-07
KR20230079520A (ko) 2023-06-07
PL3215193T3 (pl) 2024-03-18
AU2015342908A1 (en) 2017-05-04
EP3215193A4 (en) 2018-07-25
WO2016073825A1 (en) 2016-05-12
SMT202400028T1 (it) 2024-03-13
SG11201702798PA (en) 2017-05-30
RS65015B1 (sr) 2024-01-31
CN107530403A (zh) 2018-01-02
MX389844B (es) 2025-03-04
EP4282485A2 (en) 2023-11-29
PH12017500617B1 (en) 2024-07-03
KR102540109B1 (ko) 2023-06-02
LT3215193T (lt) 2024-01-25
TW201618808A (zh) 2016-06-01
US20250186552A1 (en) 2025-06-12
UA122867C2 (uk) 2021-01-13
HUE064909T2 (hu) 2024-04-28
US12343381B2 (en) 2025-07-01
NZ730924A (en) 2022-04-29
PT3215193T (pt) 2023-12-15
KR20170083074A (ko) 2017-07-17
EP3215193B1 (en) 2023-10-04
JP2017533192A (ja) 2017-11-09
IL251627B (en) 2021-12-01
ES2966888T3 (es) 2024-04-24
IL251627A0 (en) 2017-06-29
BR112017009193A2 (pt) 2018-01-30
CA2964390A1 (en) 2016-05-12
EA037151B1 (ru) 2021-02-11
EP4282485A3 (en) 2024-01-17
TWI737583B (zh) 2021-09-01
SI3215193T1 (sl) 2024-02-29
FI3215193T3 (fi) 2023-12-28
US20230131552A1 (en) 2023-04-27
EA201790991A1 (ru) 2017-11-30
HK1243627A1 (zh) 2018-07-20
US11559567B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
US12343381B2 (en) Dosage regimen for pegylated interferon
TWI241913B (en) Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
TWI272948B (en) HSA-free stabilized interferon liquid formulations
HU227310B1 (en) Method for prepaering of pharmaceutical compositions with reduced side effects containing consensus human leucocyte interferon, and new use of them
ES2239953T3 (es) Tratamiento del carcinoma de celulas renales.
ES2991384T3 (es) Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C)
JPH06340549A (ja) ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法
ES2929379T3 (es) Métodos para el tratamiento de infecciones por coronavirus
US20170157158A1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
EP3570849B1 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US20240423983A1 (en) Enhancement of cd47 blockade therapy with dhfr inhibitors
ES2243166T3 (es) Terapia de la leucemia mieloide cronica (cml).
WO2025180355A1 (zh) Il-15前药与免疫检查点抑制剂的组合
CN114028544A (zh) 一种动员淋巴瘤和骨髓瘤干细胞的药物组合物
Sweetman et al. Blood component and immunotherapy in neonatal sepsis
Thurau et al. Immunomodulatory therapy in uveitis
JPH0219325A (ja) 感染症を防除するためのヒト免疫グロブリンおよびインターロイキン―２の組み合わせ
Hartmann Feline leukemia virus: still a major cause of death in cats?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)